TY - JOUR
T1 - Non-fibrillar β-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors
AU - Shemer, Isaac
AU - Holmgren, Carl
AU - Min, Rogier
AU - Fülöp, Livia
AU - Zilberter, Misha
AU - Sousa, Kyle M.
AU - Farkas, Tamás
AU - Härtig, Wolfgang
AU - Penke, Botond
AU - Burnashev, Nail
AU - Tanila, Heikki
AU - Zilberter, Yuri
AU - Harkany, Tibor
N1 - Cognitive decline in Alzheimer's disease (AD) stems from the progressive dysfunction of synaptic connections within cortical neuronal microcircuits. Recently, soluble amyloid beta protein oligomers (Abeta(ol)s) have been identified as critical triggers for early synaptic disorganization. However, it remains unknown whether a deficit of Hebbian-related synaptic plasticity occurs during the early phase of AD.
PY - 2006/4
Y1 - 2006/4
N2 - Cognitive decline in Alzheimer's disease (AD) stems from the progressive dysfunction of synaptic connections within cortical neuronal microcircuits. Recently, soluble amyloid β protein oligomers (Aβols) have been identified as critical triggers for early synaptic disorganization. However, it remains unknown whether a deficit of Hebbian-related synaptic plasticity occurs during the early phase of AD. Therefore, we studied whether age-dependent Aβ accumulation affects the induction of spike-timing-dependent synaptic potentiation at excitatory synapses on neocortical layer 2/3 (L2/3) pyramidal cells in the APPswe/PS1dE9 transgenic mouse model of AD. Synaptic potentiation at excitatory synapses onto L2/3 pyramidal cells was significantly reduced at the onset of Aβ pathology and was virtually absent in mice with advanced Aβ burden. A decreased α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/N-methyl-d-aspartate (NMDA) receptor-mediated current ratio implicated postsynaptic mechanisms underlying Aβ synaptotoxicity. The integral role of Aβols in these processes was verified by showing that pretreatment of cortical slices with Aβ(25-35)ols disrupted spike-timing-dependent synaptic potentiation at unitary connections between L2/3 pyramidal cells, and reduced the amplitude of miniature excitatory postsynaptic currents therein. A robust decrement of AMPA, but not NMDA, receptor-mediated currents in nucleated patches from L2/3 pyramidal cells confirmed that Aβols perturb basal glutamatergic synaptic transmission by affecting postsynaptic AMPA receptors. Inhibition of AMPA receptor desensitization by cyclothiazide significantly increased the amplitude of excitatory postsynaptic potentials evoked by afferent stimulation, and rescued synaptic plasticity even in mice with pronounced Aβ pathology. We propose that soluble Aβols trigger the diminution of synaptic plasticity in neocortical pyramidal cell networks during early stages of AD pathogenesis by preferentially targeting postsynaptic AMPA receptors. © Federation of European Neuroscience Societies and Blackwell Publishing Ltd.
AB - Cognitive decline in Alzheimer's disease (AD) stems from the progressive dysfunction of synaptic connections within cortical neuronal microcircuits. Recently, soluble amyloid β protein oligomers (Aβols) have been identified as critical triggers for early synaptic disorganization. However, it remains unknown whether a deficit of Hebbian-related synaptic plasticity occurs during the early phase of AD. Therefore, we studied whether age-dependent Aβ accumulation affects the induction of spike-timing-dependent synaptic potentiation at excitatory synapses on neocortical layer 2/3 (L2/3) pyramidal cells in the APPswe/PS1dE9 transgenic mouse model of AD. Synaptic potentiation at excitatory synapses onto L2/3 pyramidal cells was significantly reduced at the onset of Aβ pathology and was virtually absent in mice with advanced Aβ burden. A decreased α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/N-methyl-d-aspartate (NMDA) receptor-mediated current ratio implicated postsynaptic mechanisms underlying Aβ synaptotoxicity. The integral role of Aβols in these processes was verified by showing that pretreatment of cortical slices with Aβ(25-35)ols disrupted spike-timing-dependent synaptic potentiation at unitary connections between L2/3 pyramidal cells, and reduced the amplitude of miniature excitatory postsynaptic currents therein. A robust decrement of AMPA, but not NMDA, receptor-mediated currents in nucleated patches from L2/3 pyramidal cells confirmed that Aβols perturb basal glutamatergic synaptic transmission by affecting postsynaptic AMPA receptors. Inhibition of AMPA receptor desensitization by cyclothiazide significantly increased the amplitude of excitatory postsynaptic potentials evoked by afferent stimulation, and rescued synaptic plasticity even in mice with pronounced Aβ pathology. We propose that soluble Aβols trigger the diminution of synaptic plasticity in neocortical pyramidal cell networks during early stages of AD pathogenesis by preferentially targeting postsynaptic AMPA receptors. © Federation of European Neuroscience Societies and Blackwell Publishing Ltd.
KW - Alzheimer's disease
KW - Excitatory synapse
KW - Neocortex
KW - Synaptic plasticity
KW - N-Methylaspartate/pharmacology
KW - Age Factors
KW - Reverse Transcriptase Polymerase Chain Reaction/methods
KW - alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/pharmacology
KW - Electric Stimulation/methods
KW - Male
KW - Amyloid beta-Peptides/chemistry
KW - Excitatory Amino Acid Agonists/pharmacology
KW - Immunohistochemistry/methods
KW - Synapses/drug effects
KW - Time Factors
KW - Neocortex/pathology
KW - Disease Models, Animal
KW - Animals, Newborn
KW - Receptors, AMPA/classification
KW - Gene Expression
KW - Pyramidal Cells/drug effects
KW - Action Potentials/drug effects
KW - Excitatory Postsynaptic Potentials/drug effects
KW - Mice, Transgenic
KW - Patch-Clamp Techniques/methods
KW - Alzheimer Disease
KW - RNA, Messenger/metabolism
KW - Animals
KW - Amyloid beta-Protein Precursor/genetics
KW - Mice
UR - https://www.scopus.com/pages/publications/33645989995
UR - https://www.scopus.com/pages/publications/33645989995#tab=citedBy
UR - https://www.mendeley.com/catalogue/d9681ee1-d87a-3e24-b27f-4f34bda7afed/
U2 - 10.1111/j.1460-9568.2006.04733.x
DO - 10.1111/j.1460-9568.2006.04733.x
M3 - Article
C2 - 16630051
SN - 0953-816X
VL - 23
SP - 2035
EP - 2047
JO - European Journal of Neuroscience
JF - European Journal of Neuroscience
IS - 8
ER -